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Gene expressionAlzheimer's disease (AD) is a neurodegenerative disorder of still unknown etiology and the leading cause of
dementia worldwide. Besides its main neuropathological hallmarks, a dysfunctional homeostasis of transition
metals has been reported to play a pivotal role in the pathogenesis of this disease. Dysregulation of iron (Fe)
metabolism in AD has been suggested, particularly at the level of cellular iron efﬂux. Herein, we intended to
further clarify the molecular mechanisms underlying Fe homeostasis in AD. In order to achieve this goal, the
expression of speciﬁc Fe metabolism-related genes directly involved in Fe regulation and export was assessed
in peripheral blood mononuclear cells (PBMCs) from 73 AD patients and 74 controls by quantitative PCR. The
results obtained showed a signiﬁcant decrease in the expression of aconitase 1 (ACO1; P=0.007); ceruloplasmin
(CP; P b 0.001) and amyloid-beta precursor protein (APP; P=0.006) genes inADpatients comparedwith healthy
volunteers. These observations point out to a signiﬁcant downregulation in the expression of genes associated
with ferroportin-mediated cellular Fe export in PBMCs from AD patients, when compared to controls. Taken
together, these ﬁndings support previous studies suggesting impairment of Fe homeostasis in AD, which may
lead to cellular Fe retention and oxidative stress, a typical feature of this disease.
© 2015 Elsevier B.V. All rights reserved.disease; ANCOVA, univariate
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Alzheimer's disease (AD) is the most common neurodegenerative
disorder and one of the most prevalent forms of dementia worldwide.
Currently AD affects over 35 million people and it is estimated that by
2050 approximately 80 million individuals will suffer from this disease
[1].
AD is a complex disorder in which multiple genetic and environ-
mental factors have been recognized to interact to promote its speciﬁc
clinical expression. Susceptibility to the most common form of AD
(sporadic late-onset AD) is likely to be governed by an array of common
risk alleles across a number of different genes. The causes of neuronal
degeneration in AD remain largely unknown but are presumed to result
from biochemical and pathological alterations in the brain, which
involve multiple underlying processes.
The classical pathophysiological hallmarks of AD are the presence of
toxic insoluble aggregates of amyloid-beta peptide (Aβ) in extracellular
senile plaques (SP) and intracellular neuroﬁbrillary tangles (NFT) of
Table 1
Demographic and clinical characteristics of the study population.




Age (y ± SD) 75.5 ± 7.9 68.3 ± 8.4
Gender F/M (n) 60/13 41/33
Age of onset (y ± SD) 69.2 ± 8.7 –
MMSE ± SD 13.6 ± 6.8 28.7 ± 2.0
Clinical Dementia Rating (CDR ± SD) 1.7 ± 0.8 0
Mann–Whitney Rank test was applied for comparison of age differences between cases
and control subjects (P b 0.001), and the Fisher exact test was used to evaluate difference
of proportions in gender between cases and control subjects (P= 0.001).
Key: CDR, Clinical Dementia Rating; F, female; M, male; MMSE, Mini Mental-State
Examination; SD, standard deviation.
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pathological events in AD seem to be due to the formation of dimeric
and oligomeric forms of Aβ, which are formed through site-speciﬁc
cleavage of amyloid precursor protein (APP) and accumulate in the
brain [3]. Although themechanisms underlying the process of Aβ depo-
sition are still poorly understood, several lines of evidence indicate that
free divalent metals such as iron (Fe), which mediate the formation of
oxidative radicals, could be closely involved [4–6]. Interestingly, another
important pathological ﬁnding in AD is the occurrence of Fe accumula-
tion in the regionswhere Aβ deposits and NFTs are found [7]. Abnormal
accumulation of Fe in Aβ containing plaques was therefore suggested
to cause neurotoxicity [8,9] by oxidative stress-mediated mechanisms
[10,11]. In this context, it is not surprising that dysfunctional homeostasis
of transition metals [12], namely of Fe homeostasis, is often referred as
one of the mechanisms playing a crucial role in the pathogenesis of AD
[13–16].
More than a decade ago, Rogers and co-workers provided evidence
for an important link between Fe metabolism and AD pathogenesis by
describing an iron-responsive element (IRE) in the 5′-untranslated
region (UTR) of the APP transcript [17]. Other authors reported an inter-
action between APP and ferroportin (Fpn), the only Fe exporter known
so far described in mammalians [18,19]. In particular, in vivo experi-
ments in APP-nullmice fed with a Fe-rich diet showed decreased Fe2+
efﬂux and thus increased Fe accumulation inside brain cells, a fact that
was suggested to be associated to the lack of APP expression and activity
in this experimental model [20]. In this same study, a REXXE consensus
motif found also in ferritin heavy chain (FtH) was described in APP
sequence and it was then proposed that APP possessed ferroxidase
activity, thus explaining its putative effect on Fpn-mediated iron export
in neurons of APP-null mice [20]. However, posterior studies demon-
strated that APP does not possess ferroxidase activity [21,22]. Still,
it was shown that APP indeed interacted with Fpn, promoting its
stabilization at cell surface, thus inﬂuencing cellular iron export in the
presence of extracellular apo-transferrin [23]. In agreement, soluble
APP (a form that results from APP cleavage), was also shown to modu-
late Fe efﬂux from brain microvascular endothelial cells by promoting
Fpn stabilization at the cell surface, but not through Fe oxidation [24].
Therefore, the involvement of APP in Fe homeostasis through its inter-
action with Fpn has been established. Additionally, APP shares similari-
tieswith other known Fpn partners, such as ceruloplasmin (Cp). Besides
the interaction with Fpn [23,24], the expression of both APP and Cp is
also up-regulated by proinﬂammatory cytokines [25,26], suggesting
an association between AD, Fe metabolism and immune response.
Moreover, APP was shown to bind heme oxygenase-1 (HMOX1) [27],
inhibiting the antioxidant and neuroprotective functions of this protein.
Further support to the close link between Fe metabolism and AD
comes from the demonstration that protein levels of furin, which is
responsible for the activation of β-secretases involved in the
amyloidogenic pathway, are also modulated by Fe [14,28,29]. In fact,
furin was shown to be involved in the modulation of systemic Fe
homeostasis via the production of soluble hemojuvelin [30], a known
repressor of hepcidin expression [31], the major systemic regulator of
Fe metabolism.
On the other hand, genetic variants in several Femetabolism-related
genes have been reported as risk factors for AD. These include single
nucleotide polymorphisms (SNPs) of the hereditary hemochromatosis
(HFE), transferrin (TF) and iron-responsive element binding protein 2
(IREB2) genes [32–36]. Recently, our group has reported signiﬁcant
associations between SNPs in several genes, namely TF, transferrin
receptor 2 (TFR2), aconitase 1 (ACO1) and ferroportin (SLC40A1) and
AD, supporting the involvement of speciﬁc Fe-metabolism pathways
in its pathophysiology [37]. Of notice, the signiﬁcant decrease of
SLC40A1 expression found in AD patients compared to controls sug-
gested impairment in cellular Fe efﬂux, which could explain, at least in
part, important and common features of AD pathogenesis. Several
other studies have addressed the relationship between peripheralblood Fe proﬁle and AD [38–41]. Very recently, a systematic review
and meta-analysis of 1813 AD patients and 2401 controls provided
rigorous statistical support for the hypothesis that alteration in Fe
homeostasis is underlying AD pathophysiology [42]. In particular, this
meta-analysis also supported our own ﬁndings of lower serum Fe in
AD patients while giving further evidence for Fe overload in several
speciﬁc brain regions implicated in this disease.
Herein, in order to better clarify the systemic Fe homeostasis
dysregulation in AD, we further studied the expression of speciﬁc Fe
metabolism-related genes in peripheral blood mononuclear cells
(PBMCs), particularly those involved in Fe efﬂux.
The results obtained showed a signiﬁcant decrease in the expression
of genes involved in Fe metabolism regulation (ACO1) and cellular Fe
export (CP and APP) in PBMCs of AD patients compared with controls.
The present ﬁndings reinforce previous data suggesting impairment of
cellular Fe efﬂux in AD patients which may contribute to the cellular
Fe accumulation and oxidative stress described in this disease.
2. Materials and methods
2.1. Study population
A total of 73 AD patients and 74 healthy Caucasian subjects were
enrolled in this study (Table 1). Patients were evaluated by neurologists
with longstanding expertise in AD, and all patients were subjected
to detailed clinical history and neurological examination, as well as to
relevant laboratorial test. Diagnosis of AD was made in accordance to
the guidelines of theNational Institute of Neurological and Communica-
tive Disorders and Stroke and Alzheimer's Disease and Related Disor-
ders Association (NINCDS-ADRDA) [43]. Both patients and controls
were recruited from the same geographical area, and constitute a sub-
set of the population analyzed previously by Crespo and co-workers
[37]. The Mann–Whitney Rank test was applied for comparison of age
differences between cases and control subjects, and the Fisher exact
test was used to evaluate difference of proportions in gender between
cases and control subjects. The results show that cases are signiﬁcantly
older than control subjects (P b 0.001) and that there is a signiﬁcant dif-
ference in the distribution of genders between cases and control sub-
jects (P = 0.001), hence all statistical analyses were adjusted for age
and gender (as described in each section).
The ethical committees of the Hospital Santa Maria/Faculdade de
Medicina da Universidade de Lisboa and Hospital Prof. Dr. Fernando
Fonseca in Lisbon approved the study, and all participants or their
legal representatives signed a written informed consent form in accor-
dance with the Declaration of Helsinki.
2.2. Measurement of biochemical markers
Whole blood samples were collected from all participants and
serum was subsequently isolated. Cp concentration was measured by
immunonephelometry in a Beckman Array® 360 System (Beckman
Coulter, Brea, CA, USA) and serum Cp oxidase activity (CPO) was
2118 C. Guerreiro et al. / Biochimica et Biophysica Acta 1852 (2015) 2116–2122assessed using amanual colorimetric assay, following a protocol adapted
from Schosinsky and co-workers [44].
PASW Statistics 18.0® (SPSS Inc.) software was used to perform the
univariate analysis of variance of biochemical data, adjusted for age and
gender (ANCOVA).2.3. Quantitative PCR
Approximately 16 mL of whole blood were collected per participant
by venipuncture into two BD Vacutainer CPT glass tubes (Becton–
Dickinson, Franklin Lakes, NJ USA). Within two hours of blood collec-
tion, PBMCs were isolated from the CPT tubes by centrifugation,
double- washed with PBS and preserved on RNA later (Qiagen, Hilden,
Germany). Total RNA was extracted from PBMCs using the miRNeasy
Mini kit (Qiagen) according to manufacturer's instructions, aliquoted
and stored at−80 °C.
Quantiﬁcation of Fe metabolism-related gene expression was
performed by quantitative PCR on ViiA™ 7 Real-Time PCR System
(Applied Biosystems,Warrington, UK). Primerswere designed to amplify
speciﬁc amplicons forHPRT1, FURIN, FTH, FTL, ACO1, TF,HMOX1NRF2, APP
and CP, using the ABI Primer Express software (Applied Biosystems)
(Supplementary Table S1).
First strand cDNA synthesis was performed using 1 μg of total
RNA extracted from PBMCs of 52 control and 51 AD individuals,
oligo(dT)12–18 and the SuperScript® II Reverse Transcriptase
(Invitrogen, Pasadena, USA), according to the manufacturer's instruc-
tions. Each cDNA sample was diluted 5-fold and 5 μL of this dilution
was then added to 5 pmol of primers and SYBR Green Master Mix
(Applied Biosystems) to a ﬁnal reaction volume of 15 μL. The cycling
parameters used were 10 min at 95 °C, followed by 40 cycles of 15 s at
95 °C and 30 s at 60 °C. Quantiﬁcation of gene expressionwasperformed
by the 2−ΔΔCtmethod usingHPRT1 as an endogenous control and a pool
of cDNAs as a normalizing sample. SPSS 18.0® softwarewas used to per-
form the univariate analysis of variance of gene expression data, adjust-
ed for age and gender (ANCOVA).2.4. Quantitative trait loci
Quantitative trait loci (QTL) analyses were performed to test the
main effect of each SNPpreviously associatedwith ADon the expression
(eQTLs) of the tested Fe metabolism-related genes (FURIN, FTH, FTL,
ACO1, TF, HMOX1, NRF2, APP and CP). For each SNP, expression data
was regressed onto genotype counts in a regressionmodel that included
gender, age, and affection status as covariates. The SNPassoc v.1.4-9
package [45] implemented in the R freeware (http://cran.r-project.
org/) was used for logistic regression analysis. Results were considered
signiﬁcant below the conventional level of 0.05.3. Results
3.1. Expression of the APP, CP and ACO1 genes is decreased in AD patients
In order to clarify themolecularmechanisms thatmight be involved
in the dysregulation of Fe homeostasis in AD, we have measuredmRNA
levels of several Fe metabolism-related genes in PBMCs from AD
patients and respective controls, as well as the serum Cp concentration
and oxidase activity. Results obtained from quantitative PCR analysis
showed a signiﬁcant decrease in the expression of ACO1 (P = 0.007),
CP (P b 0.001) and APP (P = 0.006) genes in AD patients compared to
healthy volunteers. No signiﬁcant differences between these two
groups were observed in the expression of FURIN, FTH, FTL, TF, HMOX1
and NRF2 genes (Fig. 1), nor in serum Cp concentration and oxidase
activity (Table 2).3.2. Genetic variants in genes associated with AD correlate with iron-
related gene expression
In a previous study, six SNPs in four Fe metabolism-related
genes were nominally associated with AD susceptibility, namely
one in SLC40A1 (rs1439816), three in TF (rs4428180, rs1358024, and
rs8177277), one in TFR2 (rs7385804), and one in ACO1 (rs10970973).
Associated alleles in TF and TFR2 were related to AD protection, while
in SLC40A1 and ACO1 were associated with AD risk [37]. Herein, in
order to evaluate the effect of the above mentioned variants on the ex-
pression of FURIN, FTH, FTL, ACO1, TF, HMOX1, NRF2, APP and CP genes,
eQTL analyses were performed. The results obtained (Table 3) showed
a signiﬁcant correlation between SNP rs4428180 in TF gene and the in-
crease of FTH expression (P=0.0127). Additionally, a signiﬁcant corre-
lation was found between SNP rs7385804 in TFR2 and decreased NRF2
expression (P= 0.0294), as well as between rs10970973 in ACO1 and
decrease in both FTL and HMOX1 gene expression (P = 0.0370 and
P= 0.0305, respectively).
4. Discussion
In a previous study,we have shown a signiﬁcant decrease in SLC40A1
gene (coding for Fpn) expression levels in PBMCs alongwith alterations
in systemic Fe status in AD patients which suggested impairment of
cellular Fe efﬂux in this disease [37]. In order to clarify the molecular
mechanisms involved in Fe homeostasis dysregulation, we further
studied the expression of several Fe metabolism-related genes in
PBMCs from AD patients and respective controls, in particular those
considered to play an important role in Fpn-mediated cellular Fe export.
In this study, we have found a signiﬁcant decrease in the expression
of CP (P b 0.001) and APP (P = 0.006) genes in AD patients compared
with healthy volunteers. Both Cp and APP proteins have been suggested
to be involved in cellular Fe efﬂux through interaction with Fpn [23,24,
46–48]. Therefore, the present ﬁndings further corroborate our hypoth-
esis of impairment on cellular Fe export as a keymechanism underlying
AD pathogenesis.
Cp is expressed either as a soluble protein secreted into the extracel-
lular milieu (sCp) or as a membrane protein anchored to cell surface by
a glycosylphosphatidylinositol (GPI) motif [49,50]. While hepatocytes
express and secrete high levels of sCp, GPI-anchored Cp (GPI-Cp) consti-
tutes the predominant form of Cp expressed in the brain, where it plays
a crucial role in Fe homeostasis and in anti-oxidant defense [49,51]. The
ferroxidase activity of both Cp isoforms has been reported to be crucial
for Fpn-mediated iron export. Thus, the impaired Cp expression seen in
Cp−/− mice and in aceruloplasminemia patients could explain iron
accumulation in different tissues, including the brain [52,53]. Herein,
we have measured the concentration of sCp as well as its oxidase
activity in serum, but no signiﬁcant differences were found between
AD patients and controls. Still, themain source of serum Cp is of hepatic
origin, which could explain the lack of correlation between serum Cp
expression/activity and the results of gene expression found in PBMCs.
Nonetheless, serum Cp corresponds only to the soluble isoform of this
protein, while GPI-Cp is the main Cp isoform found in the brain and
which is not accessible in the serum. In fact, GPI-Cp is also expressed
in PBMCs and it is possible that the decrease of total CP mRNA levels
in these cells could represent a decrease of GPI-Cp corresponding
mRNA. Thus, one cannot discard that Cp, and particularly GPI-Cp
expression or oxidase activity, could be altered in PBMCs, as well as, in
the brain of the patients studied. In this context, our ﬁndings provide
support for a role of impaired Fe metabolism in AD, through a change
in Cp function as a partner of Fpn in the cellular Fe export axis. In fact,
previous results from our group not only showed that human PBMCs
constitutively express both soluble and membrane-anchored Cp
isoforms [48,54], but also that GPI-Cp partially co-localizes with Fpn in
lipid rafts of Fe-treated macrophages, where it could facilitate Fe export
[48].Moreover, this GPI-Cp/Fpn partial co-localizationmay indicate that
Fig. 1. Expression levels of several iron metabolism genes in AD patients compared to controls. The distribution of the expression levels of (A) FURIN, (B) FTH1, (C) FTL, (D) ACO1, (E) TF,
(F) HMOX1, (G) NRF2, (H) APP and (I) CP of AD patients and controls are represented by the box-plots. The quantiﬁcation was performed by normalizing each sample to a pool of
individuals and usingHPRT1 as a housekeeping gene. Dots represent themild outliers. The number of individuals analyzed is indicated in brackets. Univariate analysis of variance, adjusted
for age and gender (ANCOVA) was used to compare expression levels between the two groups.
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involved in this process, as recently shown in neurons [23].
One of the hallmarks on AD is the increased deposition of Aβ
peptides in the brain. These peptides are the result of the cleavage of
APP by secretases through the amyloidogenic-pathway. Brieﬂy, after
translation and assembly to the cytoplasm membrane, APP is cleaved
by β-secretase originating sAPP and a β-APP C-terminal fragment. The
latter is then cleaved by other secretases originating the Aβ peptides
[55,56]. Here, we show that APP mRNA expression is decreased in ADTable 2
Ceruloplasmin (Cp) and ceruloplasmin oxidase activity (CPO)measured in serum fromAD
cases and control subjects.
Parameters AD Cases Controls ANCOVA
signiﬁcance (F)
n Mean ± SD n Mean ± SD
Cp (mg/dL) 67 37.37 ± 8.75 67 34.34 ± 8.76 0.307 (1.05)
CPO 70 121.68 ± 36.70 73 116.98 ± 37.04 0.923 (0.01)
Univariate analysis of variance, adjusted for age and gender (ANCOVA) was used to
compare Cp and CPO biochemical parameters between the two groups.
Key: AD, Alzheimer's disease; ANCOVA, univariate analysis of covariance; CPO, Cp oxidase
activity; SD, standard deviation.patients PBMCs. However, one cannot state whether protein levels are
also diminished, since we also found a decreased expression of ACO1,
a known repressor of APP translation [57]. In either case, the stimulation
of the APP processing by the amyloidogenic pathway in AD could be
promoting both the production of Aβ peptides and inhibition of iron
export.
The concomitant decrease of CP, APP and SLC40A1 gene expression
thus strongly suggest a concerted dysregulation of the cellular Fe efﬂux
in PBMCs of AD patients, which points to the dysregulation of Fe
metabolism and particularly Fe export in AD. This hypothesis is further
supported by the previous ﬁndings of signiﬁcant reduction of Fpn levels
in hippocampal lysates from AD brains, which corroborate the impair-
ment of Fe export also in the brain [58].
In the current work we have also observed a decrease in the expres-
sion of ACO1 in PBMCs from AD patients, when compared to controls.
Since ACO1 (also known as Iron Responsive Protein 1, IRP1) is a key
protein in the main cellular post-transcriptional iron regulation system
(IRP/IRE network), one can speculate about the putative impact that
alterations inACO1 expression could have in themechanisms underlying
the maintenance of cellular iron homeostasis. The activity of IRP1 is
modulated by Fe levels in order to control the post-transcriptional
Table 3
Expression quantitative trait loci analysis of the iron metabolism-related genetic variants associated with AD.
Gene SNP reference Gene expression eQTLs
FURIN FTH FTL ACO1 TF HMOX1 NRF2 APP CP
SLC40A1 rs1439816 NA NA NA NA NA NA NA NA 0.3471 (D)
TF rs4428180 0.4482 (D) 0.0127 (D) ↑ 0.3403 (D) 0.2887 (D) 0.8791 (D) 0.7396 (D) 0.2146 (D) 0.0734 (D) 0.8952 (D)
TF rs1358024 0.3019 (LA) 0.5651 (LA) 0.5412 (LA) 0.7102 (LA) 0.7764 (LA) 0.7720 (LA) 0.8494 (LA) 0.4162 (LA) 0.1239 (LA)
TF rs8177277 NA NA NA NA NA NA NA NA NA
TFR2 rs7385804 0.3882 (LA) 0.1464 (LA) 0.1988 (LA) 0.5875 (LA) 0.9711 (LA) 0.0681 (LA) 0.0294 (LA) ↓ 0.9711 (LA) 0.7415 (LA)
ACO1 rs10970973 0.4299 (LA) 0.1198 (LA) 0.0370 (LA) ↓ 0.8456 (LA) 0.8021 (LA) 0.0305 (LA) ↓ 0.1187 (LA) 0.9924 (LA) 0.4919 (LA)
Arrows indicate the direction of the effect of the allele associated with the expression level. Signiﬁcant P-values (b0.05) are highlighted in bold.
Key: D, dominant model; eQTLs, expression quantitative trait loci; LA, log-additive model; NA, not applicable.
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genes [59]. Indeed, many proteins involved in iron homeostasis present
IREs on their mRNA 3′-UTR (TfR1, DMT1) and 5′-UTR (H-Ft, L-Ft, Fpn,
APP, among others). In particular, some studies have shown that IRPs
are implicated in Fe regulation in the brain. For instance, APP levels are
modulated by IRP1 [57] and its expression is upregulated in the
hippocampus of IREB2−/− mice [60]. Moreover, it was also shown
that downregulation of ACO1 expression is induced by hypoxia [61].
Interestingly, a substantial body of evidence shows hypoxia as an
important environmental factor thatmay contribute to the pathogenesis
of AD [62]. Although the mechanisms by which the decrease of ACO1
expression in PBMCs of AD patients has an effect in dysregulation of Fe
homeostasis are still unknown, one cannot underestimate its putative
physiological impact, given its crucial role in this biological network.
Indeed, previous results from our group also showed an association
between rs10970973 in ACO1 and AD risk [37]. Herein, this variant
was found signiﬁcantly correlated with the decrease of both FTL and
HMOX1 gene expression. Subsequently to the decreased expression
observed in APP, CP and SLC40A1, one could expect that in physiological
conditions the putative increase in intracellular Fe would result in the
upregulation of genes with antioxidant properties (like FTL and
HMOX1). Yet, our results only have shown a non-signiﬁcant trend for
the increase of FTL and HMOX1 expression in PBMCs of AD patients.
Thus, impairment in the cellular response against oxidative stress, in
which the Fe storage and export could play an important role in reducing
ROS formation,may also be playing an important role in pathophysiology
of AD. In agreement, TF alleleswere shownassociatedwithADprotection
[37]. Furthermore, in the present studywe show a signiﬁcant correlation
between SNP rs4428180 in TF gene and the increase of FTH expression
(Table 3) suggesting that Fe storage could exert a protective role
preventing AD.
Finally, we have found a signiﬁcant association between rs7385804
in TFR2 and a decrease in NRF2 expression. It was previously reported
that the transcription factor Nrf2 modulates Fpn-mediated Fe efﬂux
[63]. Indeed, Fpn upregulation in response to heme was shown to
be mediated by Nrf2 [64]. In this study we did not ﬁnd signiﬁcant
differences between AD patients and controls concerning the mRNA
expression of NRF2, which could suggest that the observed decrease in
SLC40A1 expression is not Nrf2-dependent.
In summary, the results obtained in this study integrate several lines
of evidence that support the impairment of Fe efﬂux as a mechanism
underlyingADpathophysiology. In particular, the concomitant decrease
observed in the expression of genes directly involved in Fpn-mediated
Fe cellular efﬂux (APP and CP) and regulation (ACO1) points out to the
important role of Fe homeostasis in this disease. The results obtained
by this integrative approach, based on genetic and phenotypic data,
may be crucial to provide new directions into the development of
novel treatment strategies and to earlier and minimally invasive forms
for AD diagnosis.
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